Quantcast

Latest Placebo-controlled study Stories

2011-07-28 06:00:00

TARRYTOWN, N.Y., July 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2011 and provided an update on development programs and upcoming milestones. Clinical Programs Update EYLEA(TM) (aflibercept injection) - Ophthalmologic Diseases EYLEA(TM), also known as VEGF Trap-Eye, is a fusion protein locally administered in the eye that is designed to bind Vascular Endothelial Growth Factor-A (VEGF-A) and...

2011-07-26 14:03:12

A randomized double-blind placebo controlled trial provides the best evidence to date supporting the use of adrenaline to treat cardiac arrest Adrenaline has kept its place in cardiac arrest guidelines despite limited evidence for or against its use. The PACA (Placebo versus Adrenaline versus Cardiac Arrest) study by Jacobs and colleagues, soon to be published in Resuscitation, the official journal of the European Resuscitation Council, provides the best evidence to date supporting the use of...

2011-07-22 02:00:00

TOKYO, July 22, 2011 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Toru Usami) announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama. (Abstract no. 10428) The trial was a randomized, double-blind, placebo-controlled study with a primary...

2011-07-14 07:16:39

(Ivanhoe Newswire)--Placebos are often referred to as "dummy pills" in research trials for new drug therapies, but whether or not placebos can actually influence objective measures of disease has been unclear. A recent study led by Harvard Medical School investigators at Brigham and Women's hospital (BWH) and Beth Israel Deaconess Medical Center, analyzed the impact of two placebo treatments versus standard medical treatments in asthma patients. The study concluded that when it came to...

2011-06-27 07:30:00

ROCKVILLE, Md., June 27, 2011 /PRNewswire/ -- Glycotex, Inc., a clinical stage biopharmaceutical company, announced today that it has submitted the final results of the two completed Phase II clinical studies of its drug product candidate, GLYC-101 gel, to the clinicaltrials.gov database. These clinical studies have evaluated the effect of investigational GLYC-101 on wound closure in patients undergoing carbon dioxide laser skin resurfacing. The pilot randomized, double-blind,...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announce Phase III study results for linagliptin, demonstrating improved glycemic control in adults with type 2 diabetes (T2D) whose blood sugar is not adequately controlled. In the open-label arm (n=66) of a 24-week study in adult patients with T2D with a mean baseline hemoglobin A1c (HbA1c or A1C) of 11.8 percent receiving linagliptin 2.5 mg twice daily (bid) plus metformin 1000 mg...

2011-06-24 09:30:00

PRAGUE, Czech Republic, June 24, 2011 /PRNewswire/ -- The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course of rituximab for remission induction and maintenance over a period of 18 months proved to be as effective as standard therapy....

2011-06-22 06:30:00

EVANSTON, Ill., June 22, 2011 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13. GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), is initially being developed as a therapy for patients who are not achieving an adequate response to their current...

2011-06-17 21:06:39

Trial found no major safety concerns; larger studies needed A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These results are encouraging, but larger studies are needed to further investigate the safety and efficacy of etanercept. Results of this clinical trial are available in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of...

2011-06-16 16:20:00

SUNRISE, Fla., June 16, 2011 /PRNewswire/ -- Bioheart, Inc. (OTC Bulletin Board: BHRT) is one of the Emerging Biotech Presenters at the International Academy of Cardiology, 16th World Congress on Heart Disease, Annual Scientific Sessions- July 23rd-26th in Vancouver at the Hyatt Regency Vancouver. Howard J. Leonhardt, Bioheart's Founder and Chief Technology Officer, will be presenting on Myoblast Transplantation for Heart Repair, a Review of the State of Field. His presentation will take...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related